



Innovations in Diagnosis, Prognostic Evaluation, and Therapeutic Management of Gynecologic Tumors

Guest Editors:

Dr. Donatella Santini

Pathology Unit, IRCCS Azienda
Ospedaliero-Universitaria di
Bologna, 40138 Bologna, Italy

Dr. Antonio De Leo

1. Department of Experimental,
Diagnostic and Specialty
Medicine, University of Bologna-
Molecular Diagnostic Unit,
Azienda USL di Bologna, 40138
Bologna, Italy
2. Division of Molecular
Pathology, IRCCS Azienda
Ospedaliero-Universitaria di
Bologna, 40138 Bologna, Italy

Deadline for manuscript
submissions:

closed (15 April 2024)

Message from the Guest Editors

Diagnostic and therapeutic innovations in the field of gynecologic oncology are revolutionizing the clinical management of our patients. The refinement of integrated histopathologic and molecular classification may now contribute to a more accurate therapeutic approach for the treatment of gynecologic tumors. The innovations that the molecular classification of gynecologic tumors enables should translate into the possibility of improved diagnostic, prognostic, and therapeutic tools, with clear translational potential, to assist the clinical management of our patients.

In this context, the emergence of the multidisciplinary and multimodal integration of current gynecologic cancer news becomes important.

The development of new, targeted therapies based on cancer genomics research requires systematic and multidisciplinary approaches that are now available and that will lead to the implementation of personalized treatments in the future.

This Special Issue focuses on emerging innovations that have the potential to improve the diagnosis, prognostic evaluation, and therapeutic management of gynecologic tumors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)